Lantheus (NASDAQ:LNTH) Hits New 12-Month High – Time to Buy?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $107.99 and last traded at $106.8160, with a volume of 147583 shares traded. The stock had previously closed at $106.20.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LNTH. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial reiterated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 price target on shares of Lantheus in a report on Tuesday, March 17th. Finally, B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Stock Up 0.7%

The stock has a market cap of $6.96 billion, a PE ratio of 25.75 and a beta of -0.03. The business has a 50 day moving average price of $93.86 and a 200 day moving average price of $78.71. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the business earned $1.53 earnings per share. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 4.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently made changes to their positions in the company. Western Wealth Management LLC purchased a new stake in Lantheus during the first quarter worth $25,000. Smartleaf Asset Management LLC grew its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Parallel Advisors LLC increased its holdings in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in Lantheus in the second quarter valued at $36,000. Finally, Bessemer Group Inc. increased its holdings in Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.